Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
Condition: Hemophilia B Intervention: Genetic: CSL222 (AAV5-hFIXco-Padua) Sponsor: CSL Behring Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials